Chemotherapy-Induced Nausea and Vomiting (CINV) – Antiemetics

Therapy Initiation Resources

  • QOPI Measures
    • SMT26 – Serotonin Antagonist prescribed or administered with moderate/high emetic risk chemotherapy
    • SMT27 – Corticosteroids and Serotonin Antagonist prescribed or administered with moderate/high emetic risk chemotherapy
    • SMT28 – NK1 Receptor Antagonist and Olanzapine prescribed or administered with high emetic risk chemotherapy
    • SMT28a – NK1 Receptor Antagonist (aprepitant, fosaprepitant, netupitant) or Olanzapine administered for low or moderate emetic risk Cycle 1 chemotherapy (Lower Score – Better)
    • SMT29 – Antiemetics prescribed or administered appropriately with moderate/high emetic risk chemotherapy
      • SMT29a – Antiemetic therapy prescribed for highly emetogenic chemotherapy risk
      • SMT29b – Antiemetic therapy administered for highly emetogenic chemotherapy risk
      • SMT29c – Antiemetic therapy prescribed for moderately emetogenic chemotherapy risk
      • SMT29d – Antiemetic therapy administered for moderately emetogenic chemotherapy risk
  • CINV Slides from 2019 Biannual Meeting
  • Antiemetic Guidelines:
  • Choosing Wisely Antiemetic Recommendation
  • HOPA Time to Talk CINV Toolkit
  • ONS CINV Summary